Viking Therapeutics Files 8-K
Ticker: VKTX · Form: 8-K · Filed: Jun 4, 2024 · CIK: 1607678
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
Related Tickers: VKTX
TL;DR
Viking Therapeutics filed an 8-K. Check for updates.
AI Summary
On June 4, 2024, Viking Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or new material events were detailed in the provided excerpt, but it establishes the filing date and company information.
Why It Matters
This filing indicates Viking Therapeutics is providing updates or disclosures required by the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific financial or operational risks.
Key Players & Entities
- Viking Therapeutics, Inc. (company) — Registrant
- June 4, 2024 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
- 9920 Pacific Heights Blvd, Suite 350, San Diego, California 92121 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Viking Therapeutics, Inc.?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is June 4, 2024.
In which state is Viking Therapeutics, Inc. incorporated?
Viking Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Viking Therapeutics, Inc.?
The principal executive office is located at 9920 Pacific Heights Blvd, Suite 350, San Diego, California 92121.
What is the company's telephone number as listed in the filing?
The company's telephone number is (858) 704-4660.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-06-04 07:10:11
Key Financial Figures
- $0.00001 — ch Registered Common Stock, par value $0.00001 per share VKTX The Nasdaq Stock Mar
Filing Documents
- vktx-20240604.htm (8-K) — 40KB
- vktx-ex99_1.htm (EX-99.1) — 119KB
- img201808844_0.jpg (GRAPHIC) — 13KB
- 0000950170-24-068297.txt ( ) — 308KB
- vktx-20240604.xsd (EX-101.SCH) — 30KB
- vktx-20240604_htm.xml (XML) — 5KB
01. Regulation FD
Item 7.01. Regulation FD. On June 4, 2024, Viking Therapeutics, Inc. issued a press release announcing results from its Phase 2b VOYAGE study of VK2809. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information furnished under this Item 7.01 (Regulation FD Disclosure) of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated June 4, 2024. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIKING THERAPEUTICS, INC. Date: June 4, 2024 By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President and Chief Executive Officer (Principal Executive Officer)